A Phase III Randomized Study of BAY 43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer.

Trial Profile

A Phase III Randomized Study of BAY 43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Apr 2017

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Renal cancer; Renal cell carcinoma
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms TARGET
  • Sponsors Bayer
  • Most Recent Events

    • 11 Oct 2016 Results assessing genetic basis of sorafenib toxicity presented at the 41st European Society for Medical Oncology Congress.
    • 09 Nov 2012 Pharmacogenomic substudy results presented at the 24th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics.
    • 12 Jul 2011 Additional trial identifier (ACTRN12605000643673, 000834), additional lead trial centre identified, planned patient number is 884 and trial status is active, no longer recruiting as reported by Australian New Zealand Clinical Trials Registry.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top